Biopharmaceutical News and Research

RSS

Australian-made vaccine will protect against bird flu

An Australian-made vaccine which now has approval from the Therapeutic Goods Administration (TGA) could be used in the event of a bird flu pandemic.

17 Jun 2008

PolyTherics and Alligator Bioscience announce strategic collaboration for optimisation of next generation biopharmaceuticals

PolyTherics Ltd, a biopharmaceutical company specialised in the targeted application of polymers to biopharmaceuticals, and Alligator Bioscience AB ("Alligator"), a biotechnology company applying proprietary technology to the improvement of proteins, today announced the establishment of a new alliance.

16 Jun 2008

Biopharmaceutical manufacturing capacity to increase 66% in Europe by 2012, sccording to new report

Production capacity for biopharmaceutical manufacturing will expand an average of 46% over the next five years for mammalian production systems, according to a new report by BioPlan Associates.

2 Jun 2008

Arana and Greenovation in anti-cancer co-development deal

Arana Therapeutics Limited and Germany-based greenovation Biotech GmbH have entered into a collaborative agreement to develop next generation anti-cancer antibodies.

2 Jun 2008

U.S. Patent Office confirms second of four Viread patents

Gilead Sciences, Inc. has announced that the U.S. Patent & Trademark Office (PTO) has completed the second of four reexamination proceedings and has confirmed the patentability of U.S. Patent No. 5,922,695, which covers the composition of matter for Viread (tenofovir disoproxil fumarate). On May 20, Gilead announced that the U.S. PTO confirmed the patentability of U.S. Patent No. 6,043,230.

2 Jun 2008

Novel approach to drug insolubility strengthens PolyTherics patent estate

Polytherics Ltd, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy that specialises in the targeted application of polymers to biopharmaceuticals, has announced the grant of a European patent on the application of polymer complexation technology to improve drug efficacy.

28 May 2008

AstraZeneca supports transparency legislation on payments to health care providers

AstraZeneca announced today that it supports the revised Physician Payment Sunshine Act as part of the company's latest step to provide the public with more information about the way it does business.

22 May 2008

Patent claims allowed covering Samaritan's Alzheimer's memory recovery drug in Australia

Samaritan Pharmaceuticals, a biopharmaceutical company committed to commercializing new innovative therapeutic drugs, has received notification that the claims in the patent application for "Neuroprotective Spirostenol Pharmaceutical Compositions" covering Caprospinol (SP-233) have been allowed by the Australian Patent Office.

6 May 2008

Biosimilar protein cooperation

A biosimilar protein that can be used to treat neutropenia (a side effect of cancer chemotherapy) is to be developed by Apotex Inc. of Canada in collaboration with Intas Biopharmaceuticals Limited (IBPL).

6 May 2008

Geron Corporation awarded UK grant funding for human embryonic stem cell research

Geron Corporation announced today two grant awards to the University of Edinburgh from the UK Stem Cell Foundation, with funding from the Medical Research Council and Scottish Enterprise.

6 May 2008

Gene therapy restores vision in patients with rare congenital blindness

In a clinical trial at The Children's Hospital of Philadelphia, researchers from The University of Pennsylvania have used gene therapy to safely restore vision in three young adults with a rare form of congenital blindness.

27 Apr 2008

Biopharmaceutical spin-out company Domainex, secures funding

Headquartered in London, Domainex is a contract research company specialising in the provision of structural biology and chemistry services to major pharmaceutical and biotechnology firms. The Company is also developing a pipeline of pre-clinical drugs and targets.

From Domainex 23 Apr 2008

Takeda to acquire Millennium for $8.8 billion

Takeda Pharmaceutical Company Limited and Millennium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement pursuant to which Takeda will acquire Millennium for approximately $8.8 billion through a cash tender offer of $25.00 per share.

10 Apr 2008

Discovery of gene variant linked to nicotine addiction and lung cancer

Scientists have identified a genetic variant that not only makes smokers more susceptible to nicotine addiction but also increases their risk of developing two smoking-related diseases, lung cancer and peripheral arterial disease.

3 Apr 2008

New nanoparticles for targeting tumors

As a wide variety of nanoparticles continue to demonstrate their ability to improve the delivery of imaging agents and drugs to tumors, nanoparticle researchers have turned their attention to the challenge of systematically determining how a given nanoparticle’s physical and chemical characteristics affect its ability to target tumors. Such data could provide drug developers with guidelines to help them select the most effective type of nanoparticle for a given therapeutic or imaging application.

28 Mar 2008

NicOx signs agreement for commercial manufacture of Naproxcinod drug substance

NicOx S.A. (Euronext Paris: COX) has announced it has signed an agreement with the fine chemical company Archimica, for the commercial manufacturing and supply of naproxcinod drug substance (or active pharmaceutical ingredient, API).

20 Mar 2008

Fugitive cancer cells can be blocked by stopping blood cells that aid them

Cancer cells get a helping hand from platelets, specialized blood cells involved in clotting.

10 Mar 2008

Experimental cancer drug MI-219 promising in preclinical studies

Researchers have long searched for a novel cancer drug that activates a certain protein to kill tumor cells.

4 Mar 2008

FDA approves Aloxi injection for prevention of postoperative nausea and vomiting

Eisai Corporation of North America, its U.S. subsidiary, MGI PHARMA, INC., and Helsinn Healthcare SA today announced that the U.S. Food and Drug Administration (FDA) has approved Aloxi (palonosetron hydrochloride) injection for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.

4 Mar 2008

Nasal vaccine for smallpox protects animals against 77 times the potentially lethal dose of smallpox

Scientists at NanoBio Corporation and the University of Michigan have demonstrated their nasally delivered vaccinia vaccine can protect animals against 77 times the potentially lethal dose of smallpox, and without the safety risks of current vaccines for smallpox.

27 Feb 2008